miR-29 Is a Major Regulator of Genes Associated with Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
MicroRNAs (miRNA) are small regulatory RNAs that control gene expression by translational suppression and destabilization of target mRNAs. There is increasing evidence that miRNAs regulate genes associated with fibrosis in organs, such as the heart, kidney, liver, and the lung. In a large-scale screening for miRNAs potentially involved in bleomycin-induced fibrosis, we found expression of miR-29 family members significantly reduced in fibrotic lungs. Analysis of normal lungs showed the presence of miR-29 in subsets of interstitial cells of the alveolar wall, pleura, and at the entrance of the alveolar duct, known sites of pulmonary fibrosis. miR-29 levels inversely correlated with the expression levels of profibrotic target genes and the severity of the fibrosis. To study the impact of miR-29 down-regulation in the lung interstitium, we characterized gene expression profiles of human fetal lung fibroblast IMR-90 cells in which endogenous miR-29 was knocked down. This confirmed the derepression of reported miR-29 targets, including several collagens, but also revealed up-regulation of a large number of previously unrecognized extracellular matrix–associated and remodeling genes. Moreover, we found that miR-29 is suppressed by transforming growth factor (TGF)–β1 in these cells, and that many fibrosis-associated genes up-regulated by TGF-β1 are derepressed by miR-29 knockdown. Interestingly, a comparison of TGF-β1 and miR-29 targets revealed that miR-29 controls an additional subset of fibrosis-related genes, including laminins and integrins, independent of TGF-β1. Together, these strongly suggest a role of miR-29 in the pathogenesis of pulmonary fibrosis. miR-29 may be a potential new therapeutic target for this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Cellular and Molecular Mechanisms of Pain
Basbaum, A. I., Bautista, D. M., Scherrer, G., & Julius, D. (2009) · Cell · doi:10.1016/j.cell.2009.09.028 · Cited by 4,344
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349 · cited 1×
“There is increasing evidence that miRNAs are key regulators of genes involved in fibrosis in organs, such as the heart (9, 10), kidney (11), and liver (12).”
BackgroundDysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., Hill, J. A., & Olson, E. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805038105 · Cited by 1,844
NF-κB is a target of AKT in anti-apoptotic PDGF signalling
Romashkova, J. A., & Makarov, S. S. (1999) · Nature · doi:10.1038/43474 · Cited by 1,517
Non‐coding RNAs: regulators of disease
Taft, R. J., Pang, K. C., Mercer, T. R., Dinger, M., & Mattick, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2638 · Cited by 1,058
MicroRNA-Cancer Connection: The Beginning of a New Tale
Calin, G. A., & Croce, C. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0800 · Cited by 1,053
Sime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis
Liu, G., Friggeri, A., Yang, Y., Milosevic, J., Ding, Q., Thannickal, V. J., Kaminski, N., & Abraham, E. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100035 · Cited by 935 · cited 3×
“This strongly suggests that miR-21 regulates fibrosis by modulating TGF-b signaling activity (24).”
BackgroundSelf-citation
Cited by
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
MicroRNAs in Stress Signaling and Human Disease
Mendell, J. T., & Olson, E. N. (2012) · Cell · doi:10.1016/j.cell.2012.02.005 · Cited by 1,673
“…(Hill and Olson, 2008). miR-29 is downregulated under conditions of cardiovascular disease associated with fibrosis and excessive ECM production (Boon et al., 2011; Cushing et al., 2011; van Rooij et al., 2008), implicating this miRNA as a repressive mediator of fibrotic disease (Figure 3A).”
BackgroundRecent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Self-citationmiRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges
Zhou, S.-S., Jin, J.-P., Wang, J.-Q., Zhang, Z.-G., Freedman, J. H., Zheng, Y., & Cai, L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.30 · Cited by 675
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
van Rooij, E., & Olson, E. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3864 · Cited by 624
TGF-β/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29
Qin, W., Chung, A. C. K., Huang, X. R., Meng, X.-M., Hui, D. S. C., Yu, C.-M., Sung, J. J. Y., & Lan, H. Y. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010121308 · Cited by 566
Fibrotic extracellular matrix activates a profibrotic positive feedback loop
Parker, M. W., Rossi, D., Peterson, M., Smith, K., Sikström, K., White, E. S., Connett, J. E., Henke, C. A., Larsson, O., & Bitterman, P. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71386 · Cited by 548
The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury
Kriegel, A. J., Liu, Y., Fang, Y., Ding, X., & Liang, M. (2012) · Physiological Genomics · doi:10.1152/physiolgenomics.00141.2011 · Cited by 533
“Transforming growth factor (TGF)- , an important transcriptional stimulator of many extracellular matrix genes (40, 44, 63, 85), may be an important factor that downregulates miR-29s in fibrotic conditions including in renal epithelial cells (20, 72), human fetal lung fibroblasts (18), and human trabecular meshwork ce…”
BackgroundPathogenesis of Systemic Sclerosis
Pattanaik, D., Brown, M., Postlethwaite, B. C., & Postlethwaite, A. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00272 · Cited by 405
Therapeutic advances of miRNAs: A preclinical and clinical update
Chakraborty, C., Sharma, A. R., Sharma, G., & Lee, S.-S. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2020.08.012 · Cited by 402
“miR-29 is a controlling regulator of extracellular matrix synthesis and is a potential target for the therapy of pathological fibrosis [70].”
BackgroundKanasaki, K., Shi, S., Kanasaki, M., He, J., Nagai, T., Nakamura, Y., Ishigaki, Y., Kitada, M., Srivastava, S. P., & Koya, D. (2014) · Diabetes · doi:10.2337/db13-1029 · Cited by 359
Roncarati, R., Viviani Anselmi, C., Losi, M. A., Papa, L., Cavarretta, E., Da Costa Martins, P., Contaldi, C., Saccani Jotti, G., Franzone, A., Galastri, L., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.041 · Cited by 327
MicroRNAs in idiopathic pulmonary fibrosis
Pandit, K. V., Milosevic, J., & Kaminski, N. (2011) · Translational Research · doi:10.1016/j.trsl.2011.01.012 · Cited by 311
miR-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice
Xiao, J., Meng, X.-M., Huang, X. R., Chung, A. C., Feng, Y.-L., Hui, D. S., Yu, C.-M., Sung, J. J., & Lan, H. Y. (2012) · Molecular Therapy · doi:10.1038/mt.2012.36 · Cited by 293
Gallant-Behm, C. L., Piper, J., Lynch, J. M., Seto, A. G., Hong, S. J., Mustoe, T. A., Maari, C., Pestano, L. A., Dalby, C. M., Jackson, A. L., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.11.007 · Cited by 278
Epigenetic Regulation of miR-17∼92 Contributes to the Pathogenesis of Pulmonary Fibrosis
Dakhlallah, D., Batte, K., Wang, Y., Cantemir-Stone, C. Z., Yan, P., Nuovo, G., Mikhail, A., Hitchcock, C. L., Wright, V. P., Nana-Sinkam, S. P., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201205-0888oc · Cited by 267
A Systematic Review of miR-29 in Cancer
Kwon, J. J., Factora, T. D., Dey, S., & Kota, J. (2019) · Molecular Therapy Oncolytics · doi:10.1016/j.omto.2018.12.011 · Cited by 263
Zhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 259
MicroRNA29: A Mechanistic Contributor and Potential Biomarker in Atrial Fibrillation
Dawson, K., Wakili, R., Ördög, B., Clauss, S., Chen, Y., Iwasaki, Y., Voigt, N., Qi, X. Y., Sinner, M. F., Dobrev, D., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.001207 · Cited by 252
Plaisier, C. L., Pan, M., & Baliga, N. S. (2012) · Genome Research · doi:10.1101/gr.133991.111 · Cited by 190
“…regulated by the miR-29 family, (2) contain miR-29 family binding sites, (3) have functional association to ‘‘tissue invasion and metastasis’’ (e.g., collagens, metallo-proteases, etc.), and (4) be up-regulated by miR-29 family knock-down in lung fibroblasts in the Cushing et al. (2011) study.”
BackgroundInfluentialLung cancer in patients with idiopathic pulmonary fibrosis
Karampitsakos, T., Tzilas, V., Tringidou, R., Steiropoulos, P., Aidinis, V., Papiris, S. A., Bouros, D., & Tzouvelekis, A. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.03.016 · Cited by 171
“has been extensively investigated both as a potential antifibrotic mediator (110, 111)”
BackgroundmiR‐145 regulates myofibroblast differentiation and lung fibrosis
Yang, S., Cui, H., Xie, N., Icyuz, M., Banerjee, S., Antony, V. B., Abraham, E., Thannickal, V. J., & Liu, G. (2013) · The FASEB Journal · doi:10.1096/fj.12-219493 · Cited by 165
Self-citationWei, P., Xie, Y., Abel, P. W., Huang, Y., Ma, Q., Li, L., Hao, J., Wolff, D. W., Wei, T., & Tu, Y. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1873-x · Cited by 159
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Chioccioli, M., Roy, S., Newell, R., Pestano, L., Dickinson, B., Rigby, K., Herazo-Maya, J., Jenkins, G., Ian, S., Saini, G., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104304 · Cited by 129
Luchsinger, L. L., Patenaude, C. A., Smith, B. D., & Layne, M. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276931 · Cited by 127
miR-34a Inhibits Lung Fibrosis by Inducing Lung Fibroblast Senescence
Cui, H., Ge, J., Xie, N., Banerjee, S., Zhou, Y., Antony, V. B., Thannickal, V. J., & Liu, G. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0163oc · Cited by 104
Self-citationYao, Z., Li, J., Xiong, H., Cui, H., Ning, J., Wang, S., Ouyang, X., Qian, Y., & Fan, C. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00906-4 · Cited by 84
Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells
Li, J., Zhang, Y., Kuruba, R., Gao, X., Gandhi, C. R., Xie, W., & Li, S. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.068247 · Cited by 78
“A similar role of TGF- 13miR-292 was also demonstrated in a mouse model of lung fibrosis (Cushing et al., 2010).”
BackgroundmiR-34a promotes fibrosis in aged lungs by inducing alveolarepithelial dysfunctions
Cui, H., Ge, J., Xie, N., Banerjee, S., Zhou, Y., Liu, R.-M., Thannickal, V. J., & Liu, G. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00335.2016 · Cited by 66
“Our laboratory and others had previously demonstrated that dysregulation of miRNAs was a crucial mechanism underlying the pathogenesis of pulmonary fibrosis (10, 12, 25, 30, 31, 43, 45).”
BackgroundSelf-citationWang, J., Wang, Y., Wang, Y., Ma, Y., Lan, Y., & Yang, X. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444463 · Cited by 64
Mullenbrock, S., Liu, F., Szak, S., Hronowski, X., Gao, B., Juhasz, P., Sun, C., Liu, M., McLaughlin, H., Xiao, Q., et al. (2018) · Genes · doi:10.3390/genes9120588 · Cited by 35
Bibaki, E., Tsitoura, E., Vasarmidi, E., Margaritopoulos, G., Trachalaki, A., Koutoulaki, C., Georgopoulou, T., Spandidos, D., Tzanakis, N., & Antoniou, K. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8778 · Cited by 29
Yu, X., Elfimova, N., Müller, M., Bachurski, D., Koitzsch, U., Drebber, U., Mahabir, E., Hansen, H. P., Friedman, S. L., Klein, S., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.013 · Cited by 27
Metadata
- Authors
- Cushing, L., Kuang, P. P., Qian, J., Shao, F., Wu, J., Little, F., Thannickal, V. J., Cardoso, W. V., & Lü, J.
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-08-01
- Volume
- 45
- Issue
- 2
- Pages
- 287-294
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- OpenAlex
- W2120055234
- Cited by
- 502
- References
- 36
- FWCI
- 22.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.